Navigation Links
Shire plc - Statement re: Media Speculation
Date:7/11/2014

DUBLIN, July 11, 2014 /PRNewswire/ --


Not for release, publication or distribution (in whole or in part) in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. 

Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) notes the Bloomberg article this afternoon.  Shire confirms it has held a meeting with representatives of AbbVie.

This statement is being made by Shire without the prior agreement or approval of AbbVie.

A further update will be made when appropriate.  Shareholders are strongly advised to take no action in relation to AbbVie's proposal.  There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.

A copy of this announcement will be available at http://www.shire.com.  The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Notes to editors 

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

http://www.shire.com

 

CONTACTS 

Shire 

Stephanie Fagan

+1-201-572-9581

FTI Consulting (Media Adviser to the Company) 

Andrew Lorenz (London)

+44-77-7564-1807

Ben Atwell (London)

+44-20-3727-1000

David B. Roady (New York)

+1-212-850-5600

Robert Stanislaro (New York)

+1-212-850-5600



'/>"/>
SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Launches Online Educational Resource Center for US Patients with Ulcerative Colitis
2. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
3. Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
4. Shire to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
5. Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
6. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. Shire Reaches Agreement in Principle With U.S. Government
9. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
10. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
11. Shire Changes its NASDAQ Ticker Symbol to SHPG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):